10x GenomicsNASDAQ: TXG

Project 87% complete; plant tie-in schedule moves to February; first copper concentrate expected in Q1 (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - October 30, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides a Q3 2024 update on the development of its Media Luna Project ("Media Luna") and increases 2024 production guidance with a decision to undertake the tie-ins and upgrades to the processing plant in February 2025. Unless otherwise stated, progress and milestones referenced in this press release are as of September 30, 2024.

10x Genomics, Inc. TXG reported a loss for the third quarter on Tuesday.

10x Genomics, Inc. (NASDAQ:TXG ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Cassie Corneau - Senior Director, Head of Investor Relations and Strategic Finance Serge Saxonov - Chief Executive Officer and Co-Founder Adam Taich - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies Doug Schenkel - Wolfe Research Dan Arias - Stifel Nicolaus Dan Brennan - TD Cowen Mason Carrico - Stephens Puneet Souda - Leerink Partners Rachel Vatnsdal - J.P. Morgan Kyle Mikson - Canaccord Genuity Patrick Donnelly - Citi Michael Ryskin - Bank of America Subbu Nambi - Guggenheim Securities Matt Larew - William Blair Matt Sykes - Goldman Sachs Operator Thank you for standing by.

The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

10x Genomics (TXG) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.51 per share a year ago.

PLEASANTON, Calif. , Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024.

Per a preliminary report from 10x Genomics, the company's revenues will decline for the third quarter. Lower Instruments sales are likely to have been partially offset by consumable sales growth.

10x Genomics (TXG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.